期刊文献+

老年患者使用新型口服抗凝药物治疗时需要注意的问题 被引量:1

Points needing attention in application of new oral anticoagulants in elderly patients
下载PDF
导出
摘要 新型口服抗凝药物(NOACs)的问世,为静脉血栓栓塞症患者带来了治疗上的便利。但是,对于老年患者,由于基础疾病较多、可能同时服用多种药物等原因,在使用NOACs时需要注意一些问题,如脏器功能不全时的药物调整、如何实现抗凝药物之间的相互转换、进行有创性操作时抗凝药物的使用以及发生出血时的处理等。本文主要针对老年患者在使用NOACs时需要注意的一些问题进行阐述,以利于更加合理地使用NOACs并减少由于药物使用不当所造成的危害。 The development of new oral anticoagulants (NOACs) has brought more convenience in treatment of venous thromboembolism. However, with regard to the elderly, due to their co-existing comorbidities and multiple medication use, there are some points needing special attention in the use of NOACs, such as drug adjustment in the patients with organ dysfunctions, switch among different anticoagulants, use of anticoagulants in course of invasive manipulations, management during hemorrhages and so on. This article aimed to illustrate some points, to which attention should be paid in the use of NOACs in the elderly so as to obtain more rational NOACs use and reduce the damages caused the improper use.
作者 杨媛华 张萌
出处 《中华老年多器官疾病杂志》 2015年第12期936-939,共4页 Chinese Journal of Multiple Organ Diseases in the Elderly
基金 国家“十二五”科技支撑计划课题(2011BAI11B17)
关键词 老年人 静脉血栓栓塞症 抗凝剂 elderly venous thromboembolism anticoagulants
  • 相关文献

参考文献15

  • 1Camm AJ, Lip GY, De Caterina R, et al. 2012 Focused update of the ESC Guidelines for the Management of Atrial Fibrillation: an update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation-developed with the special contribution of the European Heart Rhythm Association[J]. Europace, 2012, 14(10): 1385-1413.
  • 2Lega JC, Bertoletti L, Gremillet C, et al. Consistency of safety profile of new oral anticoagulants in patients with renal failure[J]. J Thromb Haemost, 2014, 12(3): 337-343.
  • 3Zhang D, Frost CE, He K, et al. Investigating the enteroenteric reeirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats[J]. Drug Metab Dispos, 2013, 41(4): 906-915.
  • 4Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmaeokinetics and pharmaeodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study[J]. Clin Pharmaeokinet, 2010, 49(4): 259-268.
  • 5Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation[J]. Europace, 2013, 15(5): 625-651.
  • 6Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor[J]. Br J Clin Pharmacol, 2013, 76(1): 89-98.
  • 7Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban[J]. Clin Pharmacokinet, 2014, 53 (1): 1-16.
  • 8Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl): e326S-e350S.
  • 9Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary[J]. Eur Heart J, 2013, 34(27): 2094-2106.
  • 10Haas S, Bode C, Norrving B, et al. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk[J]. Vasc Health Risk Manag,2014, 10: 101-114.

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部